PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 88 filers reported holding PROGENICS PHARMACEUTICALS IN in Q1 2014. The put-call ratio across all filers is 1.23 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2020 | $17,615,000 | -21.3% | 4,635,469 | +5.5% | 0.00% | 0.0% |
Q4 2019 | $22,371,000 | +20.7% | 4,395,011 | +19.9% | 0.00% | +100.0% |
Q3 2019 | $18,531,000 | -33.3% | 3,665,843 | -18.6% | 0.00% | -50.0% |
Q2 2019 | $27,799,000 | +21.3% | 4,505,534 | -8.8% | 0.00% | 0.0% |
Q1 2019 | $22,914,000 | +5.9% | 4,938,327 | -4.1% | 0.00% | 0.0% |
Q4 2018 | $21,636,000 | -47.3% | 5,151,528 | -21.4% | 0.00% | -33.3% |
Q3 2018 | $41,081,000 | +22.6% | 6,552,438 | +57.2% | 0.00% | 0.0% |
Q2 2018 | $33,517,000 | +19.7% | 4,168,524 | +11.1% | 0.00% | +50.0% |
Q1 2018 | $27,992,000 | +36.3% | 3,752,334 | +8.7% | 0.00% | 0.0% |
Q4 2017 | $20,537,000 | -15.9% | 3,450,933 | +4.1% | 0.00% | 0.0% |
Q3 2017 | $24,406,000 | -3.1% | 3,316,243 | -10.6% | 0.00% | 0.0% |
Q2 2017 | $25,186,000 | +2.7% | 3,708,788 | +42.7% | 0.00% | 0.0% |
Q1 2017 | $24,534,000 | +37.8% | 2,598,721 | +26.1% | 0.00% | 0.0% |
Q4 2016 | $17,807,000 | +9.4% | 2,060,982 | -19.8% | 0.00% | 0.0% |
Q3 2016 | $16,271,000 | +91.4% | 2,570,277 | +27.6% | 0.00% | +100.0% |
Q2 2016 | $8,500,000 | -6.3% | 2,014,958 | -3.2% | 0.00% | 0.0% |
Q1 2016 | $9,070,000 | -36.9% | 2,080,659 | -11.3% | 0.00% | -50.0% |
Q4 2015 | $14,385,000 | -44.1% | 2,346,891 | -47.8% | 0.00% | -33.3% |
Q3 2015 | $25,728,000 | -30.2% | 4,498,137 | -9.0% | 0.00% | -25.0% |
Q2 2015 | $36,860,000 | +49.3% | 4,941,024 | +19.7% | 0.00% | +33.3% |
Q1 2015 | $24,682,000 | +3.3% | 4,127,347 | +30.6% | 0.00% | +50.0% |
Q4 2014 | $23,886,000 | +360.6% | 3,159,893 | +216.2% | 0.00% | +100.0% |
Q3 2014 | $5,186,000 | +20.9% | 999,192 | +0.3% | 0.00% | – |
Q2 2014 | $4,291,000 | +5.5% | 995,936 | +0.2% | 0.00% | – |
Q1 2014 | $4,066,000 | -37.8% | 994,414 | -33.6% | 0.00% | – |
Q4 2013 | $6,536,000 | +50.3% | 1,497,673 | +73.3% | 0.00% | -100.0% |
Q3 2013 | $4,349,000 | +33.5% | 863,972 | +18.4% | 0.00% | – |
Q2 2013 | $3,257,000 | – | 729,968 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Broadfin Capital, LLC | 1,583,925 | $8,007,000 | 1.48% |
Phocas Financial Corp. | 1,022,708 | $5,169,000 | 0.55% |
RICE HALL JAMES & ASSOCIATES, LLC | 1,776,490 | $8,980,000 | 0.32% |
FARALLON CAPITAL MANAGEMENT LLC | 7,350,000 | $37,154,000 | 0.28% |
NEXPOINT ASSET MANAGEMENT, L.P. | 716,880 | $3,624,000 | 0.23% |
J. Goldman & Co LP | 499,698 | $2,526,000 | 0.19% |
PINNACLE ASSOCIATES LTD | 1,257,098 | $6,355,000 | 0.15% |
CARILLON TOWER ADVISERS, INC. | 3,948,024 | $19,957,000 | 0.14% |
EAGLE ASSET MANAGEMENT INC | 4,504,094 | $22,768,000 | 0.12% |
Worth Venture Partners, LLC | 32,956 | $167,000 | 0.10% |